InvestSMART

Botanix Pharmaceuticals Ltd (ASX:BOT)

ALERT: Price-sensitive ASX Announcement for BOT
Current share price for BOT : $0.020 -0.002 (-7.14%)+
Announcement
Release
26 Aug 2026 5:53PM
Price at Release
$0.021
Full Release
download
Summary
Botanix Pharmaceuticals Ltd's Appendix 4E & Annual Report for the year ended 30 June 2026 highlights a challenging financial year with a net loss of $69,768,611. The company experienced a decrease in total assets and equity while managing to raise $40,000,000 through a share placement. Despite generating significant revenue in the United States, major expenditures on marketing and employee costs contributed to the negative financial results. The company issued a large number of shares to support its operations and did not report any substantial shareholders. The report reflects a strategic pivot to contain costs and streamline operations in the face of financial challenges.
Key Points
  • Botanix Pharmaceuticals Ltd reported a net loss of $69,768,611 for the year ended 30 June 2026.
  • The company's total assets decreased from $129,095,340 in 2025 to $105,975,344 in 2026.
  • Revenue from continuing operations was reported at $33,801,507, primarily generated in the United States.
  • Significant expenditures included $52,013,711 on product sales and marketing and $14,165,030 on employee and related expenses.
  • Total liabilities decreased from $47,796,411 in 2025 to $42,454,001 in 2026.
  • Botanix Pharmaceuticals issued 666,666,667 ordinary shares through a placement raising $40,000,000.
  • The company reported a basic and diluted loss per share of 3.22 cents.
  • As of 30 June 2026, the total equity was $63,521,343, down from $81,298,929 in 2025.
  • The company noted significant share-based payments of $10,409,929 for the year.
  • No substantial shareholders were reported as of 18 August 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.